Association Between FDA Label Restriction and Immunotherapy and Chemotherapy Use in Bladder Cancer.

Authors :: Parikh, Ravi B.
Adamson, Blythe J. S.
Khozin, Sean
Galsky, Matthew D.
Baxi, Shrujal S.
Cohen, Aaron
Mamtani, Ronac
Source :: JAMA: Journal of the American Medical Association. 9/24/2019, Vol. 322 Issue 12, p1209-1211. 3p.
Publication Year :: 2019
Abstract: This research letter discusses the association between label restrictions by the US Food and Drug Administration on first-line immunotherapy for advanced bladder cancer and subsequent changes in practice. [ABSTRACT FROM AUTHOR]

Subjects :: *BLADDER cancer treatment
*IMMUNOTHERAPY
*CISPLATIN
*ANTINEOPLASTIC agents
*THERAPEUTIC use of monoclonal antibodies
*ANTIGENS
*DRUG labeling
*GOVERNMENT regulation
BLADDER tumors

Full Text Access

Tools